{"id":"hds-vs-promece-cytabom","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL223253","moleculeType":"Small molecule","molecularWeight":"677.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HDS (high-dose sequential) and ProMECE/CytaBOM are multi-agent chemotherapy combinations used in lymphoma treatment. ProMECE/CytaBOM combines prednisone, methotrexate, etoposide, cyclophosphamide, doxorubicin, bleomycin, and other agents in a specific sequence. HDS represents an alternative high-dose approach. These are comparative regimens rather than a single drug entity.","oneSentence":"HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:57.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Aggressive non-Hodgkin lymphoma"},{"name":"Hodgkin lymphoma (advanced stage)"}]},"trialDetails":[{"nctId":"NCT00866203","phase":"PHASE3","title":"HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"2000-10","conditions":"High-Grade Lymphomas","enrollment":441}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HDS vs ProMECE/CytaBOM","genericName":"HDS vs ProMECE/CytaBOM","companyName":"Gruppo Italiano Studio Linfomi","companyId":"gruppo-italiano-studio-linfomi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents. Used for Aggressive non-Hodgkin lymphoma, Hodgkin lymphoma (advanced stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}